Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
· anavex life sciences corp.
AI Briefing
- Anavex Life Sciences withdraws EU marketing application for blarcamesine
- Blarcamesine was being reviewed as an add-on therapy for early Alzheimer’s disease
- Company will continue to pursue other regulatory pathways for the treatment
Advertisement